血浆淀粉样蛋白作为最早阿尔茨海默病理改变的预筛查工具
研究纳入248例主观认知下降的认知正常者,用Simoa技术测血浆Aβ40、Aβ42和tTau,以脑脊液和PET判定淀粉样蛋白异常。血浆Aβ42/Aβ40比值识别脑脊液淀粉样蛋白异常的AUC为77%,联合年龄和载脂蛋白E后AUC为83%,作为预筛查可减少51%腰椎穿刺。低血浆比值与临床进展至轻度认知障碍或痴呆相关(HR=2.0,95%CI=1.4-2.3)。
要点
- 血浆Aβ42/Aβ40比值可识别脑脊液淀粉样蛋白异常,AUC=77%(95%CI=69-84%)。
- 血浆比值联合年龄和载脂蛋白E后AUC=83%(95%CI=77-89%)。
- 血浆比值作为预筛查可减少51%腰椎穿刺,低比值与临床进展相关(HR=2.0)。
核心结论
- 血浆Aβ42/Aβ40比值有潜力作为预筛查工具,用于识别主观认知下降的认知正常个体中的阿尔茨海默病理改变。
研究设计与样本
- 研究纳入来自SCIENCe项目和Amsterdam痴呆队列的248例主观认知下降者(61±9岁,42%女性,简易精神状态检查=28±2)。
- 以脑脊液和正电子发射断层扫描判定淀粉样蛋白异常,用Simoa技术测基线血浆Aβ40、Aβ42和总tau。
- 用逻辑回归和受试者工作特征分析评估血浆水平与淀粉样蛋白状态的关联,用Cox比例风险模型评估与临床进展的关联。
主要发现
- 57例(23%)受试者脑脊液淀粉样蛋白异常。
- 血浆Aβ42/Aβ40比值和血浆Aβ42单独可识别脑脊液淀粉样蛋白异常(比值:AUC=77%,95%CI=69-84%;Aβ42:AUC=66%,95%CI=58-74%),总tau不能识别。
- 血浆比值联合年龄和载脂蛋白E后AUC=83%(95%CI=77-89%)。
- 血浆比值的约登截断值给出灵敏度76%和特异度75%,作为预筛查可减少51%腰椎穿刺;以PET为结局时应用血浆比值作为预筛查可达到相当的PET扫描数量减少。
- 低血浆比值与临床进展至轻度认知障碍或痴呆相关(HR=2.0,95%CI=1.4-2.3)。
关键数值与推荐
- 血浆Aβ42/Aβ40比值识别脑脊液淀粉样蛋白异常:AUC=77%(95%CI=69-84%)。
- 血浆Aβ42识别脑脊液淀粉样蛋白异常:AUC=66%(95%CI=58-74%)。
- 血浆比值联合年龄和载脂蛋白E:AUC=83%(95%CI=77-89%)。
- 血浆比值约登截断值:灵敏度76%,特异度75%,作为预筛查减少51%腰椎穿刺。
- 低血浆比值与临床进展至轻度认知障碍或痴呆:HR=2.0(95%CI=1.4-2.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigated the association of plasma amyloid beta (Abeta)40, Abeta42, and total tau (tTau) with the presence of Alzheimer pathological changes in cognitively normal individuals with subjective cognitive decline (SCD). METHODS: We included 248 subjects with SCD (61 ± 9 years, 42% female, Mini-Mental State Examination = 28 ± 2) from the SCIENCe project and Amsterdam Dementia Cohort. Subjects were dichotomized as amyloid abnormal by cerebrospinal fluid (CSF) and positron emission tomography (PET). Baseline plasma Abeta40, Abeta42, and tTau were measured using Simoa technology. Associations between plasma levels and amyloid status were assessed using logistic regression analyses and receiver operating characteristic analyses. Association of plasma levels with risk of clinical progression to mild cognitive impairment (MCI) or dementia was assessed using Cox proportional hazard models. RESULTS: Fifty-seven (23%) subjects were CSF-amyloid abnormal. Plasma Abeta42/Abeta40 ratio and plasma Abeta42 alone, but not tTau, identified abnormal CSF-amyloid status (plasma ratio: area under the curve [AUC] = 77%, 95% confidence interval [CI] = 69-84%; plasma Abeta42: AUC = 66%, 95% CI: 58-74%). Combining plasma ratio with age and apolipoprotein E resulted in AUC = 83% (95% CI = 77-89%). The Youden cutoff of the plasma ratio gave a sensitivity of 76% and specificity of 75%, and applying this as a prescreener would reduce the number of lumbar punctures by 51%. Using PET as outcome, a comparable reduction in number of PET scans would be achieved when applying the plasma ratio as prescreener. In addition, low plasma ratio was associated with clinical progression to MCI or dementia (hazard ratio = 2.0, 95% CI = 1.4-2.3). INTERPRETATION: Plasma Abeta42/Abeta40 ratio has potential as a prescreener to identify Alzheimer pathological changes in cognitively normal individuals with SCD. Ann Neurol 2018;84:656-666.
引用
- Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol. 2018. PMID: 30196548. doi:10.1002/ana.25334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。